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Abstract: Background: The study’s aim was to summarize the incidence and impacts of post-liver
transplant (LTx) acute kidney injury (AKI) on outcomes after LTx. Methods: A literature search
was performed using the MEDLINE, EMBASE and Cochrane Databases from inception until
December 2018 to identify studies assessing the incidence of AKI (using a standard AKI definition)
in adult patients undergoing LTx. Effect estimates from the individual studies were derived and
consolidated utilizing random-effect, the generic inverse variance approach of DerSimonian and Laird.
The protocol for this systematic review is registered with PROSPERO (no. CRD42018100664). Results:
Thirty-eight cohort studies, with a total of 13,422 LTx patients, were enrolled. Overall, the pooled
estimated incidence rates of post-LTx AKI and severe AKI requiring renal replacement therapy (RRT)
were 40.7% (95% CI: 35.4%–46.2%) and 7.7% (95% CI: 5.1%–11.4%), respectively. Meta-regression
showed that the year of study did not significantly affect the incidence of post-LTx AKI (p = 0.81).
The pooled estimated in-hospital or 30-day mortality, and 1-year mortality rates of patients with
post-LTx AKI were 16.5% (95% CI: 10.8%–24.3%) and 31.1% (95% CI: 22.4%–41.5%), respectively.
Post-LTx AKI and severe AKI requiring RRT were associated with significantly higher mortality with
pooled ORs of 2.96 (95% CI: 2.32–3.77) and 8.15 (95%CI: 4.52–14.69), respectively. Compared to those
without post-LTx AKI, recipients with post-LTx AKI had significantly increased risk of liver graft
failure and chronic kidney disease with pooled ORs of 3.76 (95% CI: 1.56–9.03) and 2.35 (95% CI:
1.53–3.61), respectively. Conclusion: The overall estimated incidence rates of post-LTx AKI and severe
AKI requiring RRT are 40.8% and 7.0%, respectively. There are significant associations of post-LTx
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AKI with increased mortality and graft failure after transplantation. Furthermore, the incidence of
post-LTx AKI has remained stable over the ten years of the study.
Keywords: Acute renal failure; Acute kidney injury; Epidemiology; Incidence; Meta-analysis; Liver
Transplantation; Transplantation; Systematic reviews
1. Introduction
Acute kidney injury (AKI) is associated with high mortality worldwide (1.7 million deaths
per year) [1–4]. Patients who survive AKI are at increased risk for significant morbidities such as
hypertension and progressive chronic kidney disease (CKD) [5]. The incidence of AKI has steadily
increased in recent years [2]. It has been suggested that AKI’s global burden is 13.3 million cases a
year [6]. In the United States, hospitalizations for AKI have been steeply rising, and data from national
inpatient sample shows that the number of hospitalizations due to AKI increased from 953,926 in 2000
to 1,823,054 in 2006 and 3,959,560 in 2014, which accounts for one hospitalization associated with AKI
every 7.5 minutes [7,8].
AKI is a common and significant complication after liver transplantation (LTx), and is associated
with increased mortality, hospital length of stay, utilization of resources, and health care costs [9–27].
Although the survival of LTx recipients has improved substantially over the past five decades, mortality
rates related to post-LTx AKI and subsequent progressive CKD remain high and are of increasing
concern [14,15,28–31]. The underlying mechanisms for post-LTx AKI appear to be complex and
differ from other medical or surgery-associated AKI [11,23–25,32–35]. Recent studies have suggested
several important factors that influence post-LTx AKI, including hepatic ischemia-reperfusion injury
(HIRI) [36–38], increased use of high-risk or marginal grafts, and transplantation of liver grafts
to sicker patients with higher Model For End-Stage Liver Disease (MELD) score or with more
comorbidities [23,39–51]. In our literature review, the reported incidences are a farrago, having
a range between 5% to 94% [10,11,14–25,28–35,39–49,52–80]. These wide variabilities are possibly due
to non-uniform definitions of AKI [10,11,14–25,28–35,39–49,52–80]. In addition, despite progress in
transplant medicine, the incidence, risk factors, and mortality associated with AKI in post-LTx patients
and their trends remain unclear [10,11,14–25,28–35,39–49,52–83].
Thus, we performed a systematic review to summarize the incidence (using standard AKI
definitions of Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE),
Acute Kidney Injury Network (AKIN), and Kidney Disease: Improving Global Outcomes (KDIGO)
classifications), risk factors, and mortality and their trends for AKI in patients undergoing LTx.
2. Methods
2.1. Search Strategy and Literature Review
The protocol for this systematic review was registered with PROSPERO (International Prospective
Register of Systematic Reviews; no. CRD42018100664). A systematic literature search of MEDLINE
(1946 to December 2018), EMBASE (1988 to December 2018) and the Cochrane Database of Systematic
Reviews (database inception to December 2018) was performed to evaluate the incidence of AKI in
adult patients undergoing LTx. The systematic literature review was conducted independently by
two investigators (C.T. and W.C.) using the search strategy that consolidated the terms “acute kidney
injury” OR “renal failure” AND “liver transplantation," which is provided in online supplementary
data 1. No language limitation was implemented. A manual search for conceivably related studies
using references of the included articles was also performed. This study was conducted by the
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [84] and
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) [85].
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2.2. Selection Criteria
Eligible studies must be clinical trials or observational studies (cohort, case-control, or cross-sectional
studies) that reported the incidence of post-LTx AKI in adult patients (age >/= 18 years old). Included
studies must provide data to estimate the incidence of post-LTx AKI with 95% confidence intervals
(CI). Retrieved articles were individually reviewed for eligibility by the two investigators (C.T. and
W.C.). Discrepancies were addressed and solved by mutual consensus. Inclusion was not limited by
the size of study.
2.3. Data Abstraction
A structured data collecting form was used to obtain the following information from each study,
including title, name of the first author, year of the study, publication year, country where the study
was conducted, post-LTx AKI definition, incidence of AKI post-LTx, risk factors for post-LTx AKI,
and impact of post-LTx AKI on patient outcomes.
2.4. Statistical Analysis
Analyses were performed utilizing the Comprehensive Meta-Analysis 3.3 software (Biostat Inc,
Englewood, NJ, USA). Adjusted point estimates from each study were consolidated by the generic
inverse variance approach of DerSimonian and Laird, which designated the weight of each study
based on its variance [86]. Given the possibility of between-study variance, we used a random-effect
model rather than a fixed-effect model. Cochran’s Q test and I2 statistic were applied to determine
the between-study heterogeneity. A value of I2 of 0%–25% represents insignificant heterogeneity,
26%–50% low heterogeneity, 51%–75% moderate heterogeneity and 76–100% high heterogeneity [87].
The presence of publication bias was assessed by the Egger test [88].
3. Results
A total of 2525 potentially eligible articles were identified using our search strategy. After the
exclusion of 1994 articles based on title and abstract for clearly not fulfilling inclusion criteria
on the basis of type of article, patient population, study design, or outcome of interest, and 417
due to being duplicates, 114 articles were left for full-length review. Thirty-six of them were
excluded from the full-length review as they did not report the outcome of interest, while 17 were
excluded because they were not observational studies or clinical trials. Twenty-three studies were
subsequently excluded because they did not use a standard AKI definition. Thus, we included
38 cohort studies [14,18,19,21,28–32,39,41–44,48,49,55–60,62–66,69,70,72–80] in the meta-analysis of
post-LTx AKI incidence with 13,422 patients enrolled. The literature retrieval, review, and selection
process are demonstrated in Figure 1. The characteristics of the included studies are presented in
Table 1.
J. Clin. Med. 2019, 8, 372 4 of 25
J. Clin. Med. 2019, 8, x; doi: FOR PEER REVIEW  www.mdpi.com/journal/jcm 
 
 
Figure 1. Outline of our search methodology. 
Figure 1. Outline of our search methodology.
J. Clin. Med. 2019, 8, 372 5 of 25
Table 1. Main characteristics of studies included in meta-analysis of AKI in patients undergoing LTx [14,18,19,21,28–32,39,41–44,48,49,55–60,62–66,69,70,72–80].
Study Year Country Procedure/Patients Number DeceasedDonor AKI Definition Incidence Mortality in AKI
O’riordan et al. [32] 2007 Ireland Deceased donor orthotopicliver transplant 350 350 (100%)
ARI/ARF; RIFLE Injury and Failure stage
within 2 weeks after transplant
ARI/ARF
129/350 (36.9%)
Dialysis
68/350 (19.4%)
1-year mortality
56/129 (43%)
Kundakci et al. [41] 2010 Turkey Orthotopic liver transplant 112 75 (67%) AKI; RIFLE criteria AKI64/112 (57.1%)
1-year mortality
23/64 (36%)
Portal et al. [55] 2010 UK Liver transplant 80 N/A AKI; AKIN criteria within 48 hours aftertransplants
AKI
30/80 (37.5%) N/A
Zhu et al. [42] 2010 China Deceased donor orthotopicliver transplant 193 193 (100%)
AKI; AKIN criteria within 28 days after
transplants
AKI
116/193 (60.1%)
Dialysis
10/193 (5.2%)
1-year mortality
30/116 (26%)
Lee et al. [56] 2010 Korea Liver transplant 431 99 (23%) AKI; RIFLE criteria
AKI
118/431 (27.4%)
Dialysis
14/431 (3.2%)
N/A
Ferreira et al. [57] 2010 Portugal Orthotopic liver transplant 708 N/A AKI; RIFLE criteria within 21 days aftertransplant
AKI
235/708 (33.2%)
Dialysis
73/708 (10.3%)
Mortality
43/235 (18%)
Tinti et al. [58] 2010 Italy Deceased donor orthotopicliver transplant 24 24 (100%)
AKI; RIFLE criteria within 15 days after
transplant
AKI
9/24 (37.5%) N/A
Chen et al. (1) [18] 2011 USA Liver transplant 334 N/A
ARI/ARF; RIFLE Injury and Failure stage
within 2 weeks after transplant within 7 days
after transplant
ARI/ARF
118/334 (38.3%)
Mortality
13/118 (11%)
Umbro et al. [59] 2011 Italy Deceased donor livertransplant 46 46 (100%)
AKI; RIFLE criteria within 7 days after
transplant
AKI
26/46 (56.5%) N/A
Karapanagiotou et al.
(1) [43] 2012 Greece Orthotopic liver transplant 75 N/A
AKI; an increase in SCr 1.5 times above
baseline or value > 2.0 mg/dL within 7 days
after transplant
AKI
22/75 (29.3%)
Dialysis
7/75 (9.3%)
1-year mortality
11/22 (50%)
Utsumi et al. [44] 2013 Japan Living donor liver transplant 200 0 (0%) AKI; RIFLE criteria within 28 days aftertransplants
AKI
121/200 (60.5%)
ARI/ARF
74/200 (37%)
Hospital mortality
AKI
14/121 (12%)
ARI/ARF
12/74(16%)
1-year mortality
AKI
24/121 (20%)
ARI/ARF
22/74 (30%)
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Table 1. Cont.
Study Year Country Procedure/Patients Number DeceasedDonor AKI Definition Incidence Mortality in AKI
Narciso et al. [60] 2013 Brazil Liver transplant 315 181 (57%) AKI; AKIN criteria within 48 hours aftertransplants
AKI
48 hours: 101/315
(32.1%)
1 week: 255/315
(81%)
Hospitalization:
293/315 (93%)
Dialysis
Any: 48/315 (15.2%)
1 week: 31/315
(9.8%)
Dialysis
28/48 (58%)
Leithead et al. [39] 2014 UK Liver transplant 1152 1152 (100%)DCD 112 (10%)
AKI; KDIGO criteria within 7 days after
transplants
AKI
381/1152 (33.1%)
Dialysis
238/1152 (20.7%)
AKI
152/381 (40%)
Karapanagiotou et al.
(2) [48] 2014 Greece Liver transplant 71 N/A
AKI; RIFLE within 7 days or AKIN criteria
within 48 hours
RIFLE AKI
28/71 (39.4%)
AKIN AKI
37/71 (52.1%)
6-month mortality
RIFLE AKI
15/28 (54%)
AKIN AKI
17/37 (46%)
Nadeem et al. [49] 2014 SaudiArabia Liver transplant 158 N/A
AKI; RIFLE criteria within 72 hours after
transplants
AKI
57/158 (36.1%) N/A
Lewandowska et al.
[62] 2014 Poland Orthotopic liver transplant 63 N/A
AKI; RIFLE criteria within 72 hours after
transplant
AKI
35/63 (55.6%) N/A
Barreto et al. [63] 2015 Brazil Orthotopic liver transplant 134 N/A AKI; AKIN criteria 2 or 3 within 72 hoursafter transplants
AKIN stage 2 or 3
64/134 (47.8%)
Dialysis
33/134 (24.6%)
N/A
Hilmi et al. [19] 2015 USA Deceased donor livertransplant 424
424 (100%)
EDC 257 (61%)
AKI; KDIGO criteria within 72 hours after
transplant
AKI
221/424 (52.1%)
30-day mortality
3/221 (1%)
Park et al. [64] 2015 Korea Living donor liver transplant 538 0 (0%) AKI; RIFLE criteria within 30 days aftertransplant
AKI
147/538 (27.3%)
Dialysis
34/538 (6.3%)
Hospital mortality
26/147 (18%)
1-year mortality
29/147 (20%)
Mukhtar et al. [65] 2015 Egypt Living donor liver transplant 303 0 (0%) AKI; AKIN criteria within 96 hours aftertransplant
AKI
115/303 (38%)
Dialysis
28/303 (9.2%)
N/A
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Table 1. Cont.
Study Year Country Procedure/Patients Number DeceasedDonor AKI Definition Incidence Mortality in AKI
Sang et al. [66] 2015 Korea Living donor liver transplant 998 0 (0%) AKI; RIFLE or AKIN criteria within 7 daysafter transplant
RIFLE AKI
709/998 (71.0%)
AKIN AKI
593/998 (59.4%)
RIFLE AKI
79/709 (11%)
AKIN AKI
66/593 (11%)
Biancofiore et al. [69] 2015 Italy Deceased donor livertransplant 295 295 (100%)
AKI; AKIN criteria within 7 days after
transplant
AKIN stage 2 AKI
51/295 (17.3%) N/A
Jun et al. [70] 2016 Korea Living donor liver transplant 1617 0 (0%) AKI; KDIGO criteria within 7 days aftertransplant
AKI
999/1617 (61.8%)
Dialysis
9/448 (2%)
N/A
Erdost et al. [72] 2016 Turkey Liver transplant 440 194 (44%) AKI; RIFLE, AKIN, KDIGO criteria within 7days after transplant
RIFLE AKI
35/440 (8.0%)
AKIN AKI
63/440 (14.3%)
KDIGO AKI
64/440 (14.5%)
30-day mortality
RIFLE AKI
8/35 (23%)
AKIN AKI
34/63 (54%)
KDIGO AKI
35/64 (55%)
Kamei et al. [73] 2016 Japan Liver transplant 62 DBD 4 (6%) AKI; RIFLE injury or failure stage within 4weeks after transplant
AKI
13/62 (21%)
Dialysis
4/62 (6.5%)
N/A
Mizota et al. (1) [74] 2016 Japan Living donor liver transplant 320 0 (0%) AKI; KDIGO criteria within 7 days aftertransplant
AKI
199/320 (62.2%)
Hospital mortality
39/199 (20%)
Sun et al. [21] 2017 USA Liver transplant 1037 N/A AKI; AKIN criteria within 48 hours aftertransplant
AKI
549/1037 (54.9%) N/A
Chae et al. [75] 2017 Korea Living donor liver transplant 334 0 (0%) AKI; AKIN criteria within 48 hours aftertransplant
AKI
76/334 (22.7%)
Hospital mortality
10/76 (13.2%)
Mizota et al. (2) [76] 2017 Japan Living donor liver transplant 231 0 (0%) Severe AKI; KDIGO stage 2 or 3 criteriawithin 7 days after transplant
Severe AKI
71/231 (30.7%)
Hospital mortality
23/71 (32.4%)
Trinh et al. [77] 2017 Canada Deceased donor livertransplant 491 491 (100%)
AKI; KDIGO criteria within 7 days after
transplant
AKI
278/491 (56.6%) N/A
Kalisvaart et al. [78] 2017 Netherlands Donation after brain deathliver transplant 155
155 (100%)
DBD 155 (100%)
AKI; AKIN criteria within 7 days after
transplant
AKI
61/155 (39.4%)
Dialysis
5/155 (3.2%)
Hospital mortality
9/61 (15%)
Chen et al. (2) [79] 2017 China Liver transplant inhepatocellular carcinoma 566 N/A
AKI; AKIN criteria within 48 hours after
transplant
AKI
109/566 (19.3%)
Dialysis
13/566 (2.3%)
30-day mortality
9/109 (8%)
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Table 1. Cont.
Study Year Country Procedure/Patients Number DeceasedDonor AKI Definition Incidence Mortality in AKI
Baron-Stefaniak et al.
[80] 2017 Austria Orthotopic liver transplant 45 N/A
AKI; KDIGO criteria within 48 hours after
transplant
AKI
34/45 (75.6) N/A
Zhou et al. [30] 2017 China
Donation after circulatory
death orthotopic liver
transplant
103 103 (100%)DCD 103 (100%)
AKI; KDIGO criteria within 7 days after
transplant
AKI
42/103 (40.8%)
CRRT
7/103 (6.8%)
N/A
Yoo et al. [31] 2017 Korea Liver transplant 304 84 (28%) AKI; RIFLE criteria within 7 days aftertransplant
AKI
132/304 (43.4%) N/A
Jochmans [29] 2017 Belgium Orthotopic liver transplant 80
80 (100%)
DCD 13 (16%)
DBD 67 (84%)
AKI; RIFLE criteria within 5 days after
reperfusion
AKI
21/80 (26.3%)
Dialysis
4/80 (5%)
1-year mortality
2/21 (10%)
Kandil et al. [28] 2017 Egypt Living donor liver transplant 50 0 (0%) AKI; AKIN criteria within 48 hours AKI23/50 (46%) N/A
Kim et al. [14] 2018 Korea Living donor liver transplant 583 0 (0%) AKI; KDIGO criteria within 7 days aftertransplant
AKI
205/583 (35.2%) N/A
Abbreviations: AKIN, Acute Kidney Injury Network; DCD, donation after circulatory death; EDC, extended donor criteria liver allografts; KDIGO, Kidney Disease Improving Global
Outcomes; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; UK, United Kingdom; USA, United States of America.
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3.1. Incidence of Post-LTx AKI
Overall, the pooled estimated incidence rates of post-LTx AKI and severe AKI requiring RRT
following LTx were 40.7% (95% CI: 35.4%–46.2%, I2 = 97%, Figure 2) and 7.7% (95% CI: 5.1%–11.4%,
I2 = 95%, Figure 3), respectively.
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Figure 2. Forest plots of the included studies assessing incidence rates of post-LTx AKI. A diamond
data marker represents the overall rate from each included study (square data marker) and 95%
confidence interval.
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Figure 3. Forest plots of the included studies assessing incidence rates of severe AKI requiring RRT
following LTx. A diamond data marker represents the overall rate from each included study (square
data marker) and 95% confidence interval.
Meta-regression showed no significant impact of type of donor (deceased vs living donors)
(p = 0.33) on the incidence of post-LTx AKI. In addition, the year of study (p = 0.81) did not significantly
affect the incidence of post-LTx AKI (Figure 4).
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3.2. Risk Factors for Post-LTx AKI
Reported risk factors for post-LTx AKI are demonstrated in Table 2. Higher pretransplant
SCr [11,23–25,32–35], high body mass index (BMI) [39,64,66,67], high MELD/MELD-Na
score [23,39–49], intraoperative blood loss and perioperative blood transfusion [18,25,39,48,54,65],
high APACHE II score [25,43,48,55], hypotension and vasopressor requirement [18,24,48,54], cold and
warm ischemia time [14,35,78], graft dysfunction [11,40,53], post-reperfusion syndrome [20,64,66,75,78],
infection prior to transplant [25,45,48], and hypoalbuminemia [18,64,66] were consistently identified
as important risk factors for Post-LTx AKI.
3.3. Impacts of Post-LTx AKI on Patient Outcomes
The impacts of post-LTx AKI on patient outcomes are demonstrated in Table 3. Overall, the pooled
estimated in-hospital or 30-day mortality, and 1-year mortality rates of patients with post-LTx AKI
were 16.5% (95% CI: 10.8%–24.3%, I2 = 94%) and 31.1% (95% CI: 22.4%–41.5%, I2 = 78%), respectively.
Post-LTx AKI was associated with significantly higher mortality with a pooled OR of 2.96 (95% CI:
2.32–3.77, I2 = 59%). In addition, severe post-LTx AKI requiring RRT was associated with significantly
higher mortality with a pooled OR of 8.15 (95% CI: 4.52–14.69, I2 = 90%). Compared to those without
post-LTx AKI, recipients with post-LTx AKI had significantly increased risks of liver graft failure and
CKD with pooled ORs of 3.76 (95% CI: 1.56–9.03, I2 = 91%, Figure 5) and 2.35 (95% CI: 1.53–3.61,
I2 = 75%, Figure 6), respectively. AKI was associated with prolonged intensive care (ICU) and hospital
stay [17,18,23,24,29,32,35,40,42,44,48,49,53,61,64,75,78] (Table 3).
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Figure 5. Forest plots of the included studies assessing liver graft failure among patients with post-LTx
AKI. A diamond data marker represents the overall rate from each included study (square data marker)
and 95% confidence interval.
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Table 2. Reported Potential Predictors/Associated-Risk Factors of Post-LTx AKI.
Donor and Graft Factors Recipient Factors Surgical and Postoperative Factors
Cold ischemia time [14,35,78],
warm ischemic time [35,39,63,64,66]
Small-for-size graft/Graft-recipient body weight
ratio [40,44,65,66]
Deceased donor [20,47]
Graft dysfunction [11,53]
DCD [39]
ABO incompatibility [70]
Lower donor BMI [39]
Older donor age [39]
Higher MELD score/MELD-Na [23,39–49,64,67,89]
APACHE II25 [43,48,55],
Preoperative SCr11 [23–25,32–35]
Preoperative BUN [23,24]
Preoperative renal dysfunction/ARF [40,43,53]
Child-Pugh score [19]
SOFA [48]
Male sex [42], female sex [19,31]
Preoperative hepatic encephalopathy [47]
Infection [25,48,71]
Hypoalbuminemia [18,53,64,66]
Preoperative low hemoglobin [14,72]
High body weight, BMI [14,19,39,44,64,66,67,75]
Pretransplant hypertension [32,54]
Preoperative DM [19,44]
Alcoholic liver disease [32]
Pretransplant hepatitis B and/or C [54,63]
Tumor as indication for transplant [47]
Elevated lactate [54,63]
Elevated plasma NGAL [55]
Hyponatremia [39]
Pulmonary hypertension [31]
Intra-operative hypotension, low MAP [24,33,34,54,66,79]
Inotrope/vasopressor requirement [18,30,32,48,65], dopamine [35], intra-operative
need of noradrenaline [33,67]
Duration of treatment with dopamine [53]
Blood loss [35,44,47,64,70,71], RBC transfusion [14,18,25,33,39,48,54,65,66,72,89]
Need of cryoprecipitate [64]
Anesthetic/Operation time [30,64,66,70]
Post-reperfusion syndrome [20,64,66,78]
SvO2 reduction with oliguria [14], Oxygen content 5 min after graft reperfusion [75]
Terlipressin (protective) [65]
Venovenous bypass (protective) [21]
Postoperative ICU days [23,48]
Duration of ventilator support [48]
Aminoglycoside use [32]
Duration of anhepatic phase [41,79]
Intra-operative acidosis [41]
Intra-operative urine output [14,24,30,33]
Overexposure to calcineurin inhibitor [35,44,64]
Need of diuretics [46,75]
Chloride-liberal fluid received within the 24 h posttransplant [49]
Crystalloid administration [14]
Use of 6% HES [89]
Mean blood glucose during the day of surgery [64], glucose variability [31]
Peak AST occurring at 6 h [29]
Abbreviations:: ABO incompatibility, incompatibility of the ABO blood group; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ALP, alkaline phosphatase; APACHE, Acute
Physiology and Chronic Health Evaluation; ARI, acute renal injury; ARF, acute renal failure; AST, aspartate aminotransferase; ATG, Anti-thymocyte globulin; BMI, body mass index; BUN,
blood urea nitrogen; CMV, cytomegalovirus; DBD, graft donated after brain death; DCD, donation after circulatory death; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate;
FFP, fresh frozen plasma; HCV, hepatitis C virus; HES, hydroxyethyl starch; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; SCr, serum creatinine; MAP,
mean arterial pressure; MELD, Model For End-Stage Liver Disease; MMF, mycophenolate mofetil; N/A, not available; NGAL, neutrophil gelatinase-associated lipocalin; PBC, primary
biliary cirrhosis; RBC, red blood cell; RRT, renal replacement therapy; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; SOFA, Sequential Organ Failure
Assessment; SvO2, mixed venous oxygen saturation.
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Table 3. Reported Outcomes of Post-LTx AKI.
Study Outcomes Confounder Adjustment
Bilbao et al. [11]
Mortality
Dialysis: 6.47 (2.73–15.35)
Graft failure
Dialysis: 4.11 (1.81–9.32)
None
Contreras et al. [24]
Hospital mortality
Dialysis: 9.91 (3.45–28.51)
ICU LOS
Dialysis: 15 ± 13 vs. 7 ± 11 days
Hospital LOS
Dialysis: 34 ± 27 vs. 19 ± 20 days
None
Lebrón Gallardo et al. [25]
Mortality
Early renal dysfunction: 2.47 (1.29–4.72)
Dialysis: 8.80 (3.65–21.23)
None
Sanchez et al. [23]
1-year mortality
Dialysis: 9.07 (5.49–14.97)
ICU LOS
2.1 ± 3.0 in no dialysis vs. 8.6 ± 11.6 in hemodialysis vs. 10.5 ± 12.8 days in CRRT
None
Wyatt et al. [22]
Mortality
ARF without RRT: 8.69 (3.25–23.19)
ARF with RRT: 12.07 (3.90–37.32)
Age, sex, race, DM, transplant centers
Cabezuelo et al. [53] ICU LOSARF: 12.9 ± 7.4 vs. 7.2 ± 4.0 days N/A
O’Riordan et al. [32]
1-year mortality
ARF: 2.6 (1.5–4.5)
Hospital LOS
39.3 ± 79.5 in no ARI/ARF vs. 53.3 ± 72.8 in ARI vs. 73.0 ± 129.8 days in ARF
DM, pretransplant, SCr, PBC, inotrope use, CMV
infection/disease, rejection
Lee et al. [40] Hospital LOSRenal dysfunction: 75 ± 144 vs. 45.2 ± 34.5 days N/A
Rueggeberg et al. [54] 1-year mortalityAKI: 10.93 (3.64–32.83) None
Barri et al. [17]
2-year mortality
AKI: 2.33 (1.53–3.53)
2-year graft failure
AKI: 2.56 (1.73–3.78)
ICU LOS
AKI: 8 ± 19 vs. 3 ± 5 days
Hospital LOS
AKI: 20 ± 24 vs. 11 ± 10 days
None
Kundakci et al. [41] 1-year mortalityAKI: 6.73 (2.15–21.06) None
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Zhu et al. [42]
1-year mortality
AKI: 12.1 (1.57–93.54)
ICU LOS
AKI: 6 (4–9) vs. 4 (3–5) days
Hospital LOS
AKI: 29 (16–47) vs. 29 (20–48) days
Hypertension, infection and APACHE II
Ferreira et al. [57]
Mortality
AKI: 0.73 (0.59–1.08)
CKD
AKI: 4.84 (3.45–6.80)
None
Lee et al. [56] CKDAKI: 1.54 (1.02–2.34)
Age, sex, period of transplant, BMI, pretransplant DM,
pretransplant hypertension, history of cardiovascular
disease, donor type, underlying liver disease,
HBV-related liver disease, hepatocellular carcinoma,
use of adefovir, calcineurin inhibitors, purine
metabolism inhibitors, acute rejection, pretransplant
hemoglobin, pretransplant GFR, pretransplant
proteinuria, hepatorenal syndrome, Child-Pugh score,
MELD score
Chen et al. [18]
1-year mortality
ARI/ARF: 2.79 (0.96–8.12)
1-year graft failure
ARI/ARF: 1.91 (0.89–4.09)
Hospital LOS
21.8 ± 22.1 in no ARI/ARF vs. 24 ± 25 in ARI and 37 ± 49 days in ARF
None
Karapanagiotou et al. [43] 1-year mortality9.61 (1.48–62.55) Infection, hemorrhage, MELD, APACHE score
Utsumi et al. [44]
Hospital mortality
AKI: 5.04 (1.11–22.81)
ARI/ARF: 5.90 (1.83–19.06)
1-year mortality
AKI: 9.53 (2.18–41.56)
ARI/ARF: 12.90 (4.24–39.30)
CKD
AKI: 15/107 (14%) vs. 0/77 (0%)
ARI/ARF: 35.29 (4.51–275.82)
Hospital LOS
ARI/ARF: 101.5 ± 68.8 vs. 69.7 ± 48.5 days
None
Narciso et al. [60] MortalityDialysis: 6.7 (3.49–12.96) None
Romano et al. [45] Hospital mortalityAKI: 1.88 (0.76–4.65) None
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Leithead et al. [39] Mortality1.71 (1.35–2.17) Age, sex, MELD score, eGFR, DM
Klaus et al. [46]
Mortality
AKI: 5.11 (1.39–18.71)
Dialysis:14.4 (4.60–45.09)
None
Kim et al. [47] 1-year mortalityDialysis: 56.5 (12.32–259.20) None
Karapanagiotou et al. [48]
6-month mortality
RIFLE: 3.08 (1.09–1.95)
AKIN: 9.34 (1.20–15.69)
ICU LOS
RIFLE: 15.44 ± 15.41 vs. 8.65 ± 12.59 days
AKIN: 13.75 ± 14.53 vs. 9.1 ± 13.08 days
Vasopressor use, RBC transfusion
Nadeem et al. [49] ICU LOSAKI: 13.4 ± 19 vs. 5.5 ± 4.7 days N/A
Kirnap et al. [61]
Mortality
AKI: 1.85 (0.65–5.23)
ICU LOS
AKI: 10 ± 8 vs. 3 ± 2 days
Hospital LOS
AKI: 26 ± 70 vs. 16 ± 7 days
None
Barreto et al. [63] Hospital mortalityAKIN stage 2 or 3: 4.3 (1.3–14.6) None
Hilmi et al. [19]
30-day mortality
AKI: 3/221(1.4%) vs. 0/203 (0%)
CKD
AKI: 1.69 (1.11–2.58)
None
Park et al. [64]
Hospital mortality
3.44 (1.89–6.25)
1-year mortality
AKI: 1.57 (0.95–2.58)
ICU LOS
6 (6–7) in no AKI vs. 6 (6–9) in Risk vs. 7 (6–18) in Injury vs. 11 (10–85) in Failure
group
Hospital LOS
29 (23–42) in no AKI vs. 31 (21–43) in Risk vs. 33 (26–47) in Injury vs. 46 (16–108) in
Failure group
None
Mukhtar et al. [65] MortalityAKI: 2.1 (1.18–4.0)
Graft weight to recipient body weight ratio, baseline
creatinine, MELD score, DM, Terlipressin use, massive
transfusion, vasopressor use
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Sang et al. [66]
Mortality
RIFLE AKI: 2.29 (1.29–4.05)
AKIN AKI: 1.69 (1.06–2.67)
None
Wyssusek et al. [67] MortalityAKI: 3.23 (0.43–24.27) None
Jun et al. [70] MortalityAKI: 0.36 (0.09–1.43)
ABO incompatibility, MELD score, hypertension,
coronary artery disease, age, post-reperfusion
syndrome, vasopressor, crystalloid, RBC transfusion,
FFP transfusion, operation time, cold ischemic time
Inoue et al. [71]
1-year mortality
AKI: 4.54 (1.27–16.32)
CKD
AKI: 2.33 (0.66–8.29)
None
Mizota et al. [74]
Hospital mortality
AKI: 2.53 (1.23–5.22)
CKD
AKI: 2.46 (1.51–4.02)
Age, MELD score, blood type incompatibility,
re-transplantation
Erdost et al. [72]
30-day mortality
RIFLE AKI: 4.15 (1.72–10.00)
AKIN AKI: 440.83 (58.24–3336.87)
KDIGO AKI: 35/64 (55%) vs. 0/376
None
Chae et al. [75]
Hospital mortality
AKI: 1.63 (0.73–3.60)
ICU LOS
AKI: 7 (6–8) vs. 7 (5–7) days
Hospital LOS
AKI: 28 (22–39) vs. 23 (21–31) days
None
Mizota et al. [76] Hospital mortalitySevere AKI: 3.56 (1.78–7.09) None
Trinh et al. [77]
Mortality
AKI: 1.41 (1.03–1.92)
CKD stage 4–5
AKI: 2.39 (1.27–4.47)
Age, sex, MELD score, baseline eGFR, ATG induction,
pretransplant hypertension and DM
Kalisvaart et al. [78]
Hospital mortality
AKI: 7.96 (1.66–38.25)
ICU LOS
AKI: 3 (2–5) vs. 2 (2–3) days
Hospital LOS
AKI: 24 (19–35) vs. 17 (14–27) days
None
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Nadkarni et al. [16] Hospital mortalityDialysis: 2.00 (1.55–2.59) Not specified
Chen et al. [79] 30-day mortalityAKI: 4.05 (1.02–16.18) ALP, MELD score, operation time, blood transfusion
Zongyi et al. [35]
1-year mortality
RIFLE failure stage AKI: 12.25 (8.99–16.70)
1-year graft failure
RIFLE failure stage AKI: 11.73 (8.57–16.06)
Hospital LOS
RIFLE failure stage AKI: 16 (6–34.5) vs. 25 (18–35) days
None
Zhou et al. [30]
14-day mortality
AKI: 3.35 (0.94–11.98)
Hospital LOS
AKI: 28.13 ± 20.04 vs. 26.16 ± 11.91 days
None
Jochmans et al. [29]
1-year mortality
AKI: 6.11 (0.52–71.16)
1-year graft failure
AKI: 2.54 (0.61–10.55)
CKD
AKI:1.17 (0.40–3.44)
ICU LOS
AKI: 4 (3–9) vs. 2 (2–4)
Hospital LOS
AKI: 23 (17–46) vs. 16 (13–26)
None
Abbreviations:: ABO incompatibility, incompatibility of the ABO blood group; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ALP, alkaline phosphatase; APACHE, Acute
Physiology and Chronic Health Evaluation; ARI, acute renal injury; ARF, acute renal failure; AST, aspartate aminotransferase; ATG, Anti-thymocyte globulin; BMI, body mass index; BUN,
blood urea nitrogen; CMV, cytomegalovirus; DCD, donation after circulatory death; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FFP, fresh frozen plasma; HCV,
hepatitis C virus; HES, hydroxyethyl starch; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; SCr, serum creatinine; MAP, mean arterial pressure; MELD,
Model For End-Stage Liver Disease; MMF, mycophenolate mofetil; N/A, not available; NGAL, neutrophil gelatinase-associated lipocalin; PBC, primary biliary cirrhosis; RBC, red blood
cell; RRT, renal replacement therapy; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; SOFA, Sequential Organ Failure Assessment; SvO2, mixed venous
oxygen saturation.
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3.4. Evaluation for Publication Bias
Funnel plot (Supplementary Figure S1) and Egger’s regression asymmetry test were performed to
evaluate for publication bias in the analysis evaluating incidence of post-LTx AKI and mortality risk of
post-LTx AKI. There was no significant publication bias in meta-analysis assessing the incidence of
post-LTx AKI, p-value = 0.12.
4. Discussion
In this meta-analysis, we found that AKI and severe AKI requiring RRT after LTx are common,
with an incidence of 40.8% and 7.0%, respectively. In addition, our findings showed no significant
correlation between the incidence of post-LTx AKI and study year for the ten years of the study.
Furthermore, compared to patients without post-LTx AKI, those with post-LTx AKI carry a 2.96-fold
increased risk of mortality and a 3.76-fold higher risk of liver graft failure.
The development of post-LTx AKI appears to be multifactorial with a number of preoperative,
intraoperative and postoperative factors involved [90]. Pre-LTx factors include high MELD/MELD-Na
score, high APACHE II score, hypoalbuminemia, and reduced eGFR [11,23–25,32–35]. Preexisting renal
impairment is common among patients with end-stage liver disease [91]. Although cirrhotic patients
with significant CKD are eligible to receive a combined liver-kidney transplantation [92], a lower
baseline GFR among those who received LTx alone remained an important risk factor for post-operative
AKI [11,23–25,32–35]. Studies have demonstrated that hepatorenal syndrome before LTx can also lead
to renal insufficiency and render LTx recipients more susceptible to post-LTx AKI [22,90,93]. In addition,
sepsis, graft dysfunction, thrombotic microangiopathy, and calcineurin inhibitor nephrotoxicity may
all contribute to AKI [22,37,94–96].
Studies have shown that higher MELD scores were associated with post-LTx AKI [23,39–49].
In patients with high MELD scores >30, the majority required RRT post LTx [44,97]. Although SCr is
an important determinant of the MELD score, other components of MELD such as pre-LTx INR has
also been demonstrated to be strongly associated with post-LT AKI, suggesting that the severity of
the liver disease itself, as reflected by the MELD score, is associated with post-LT AKI [45]. Identified
perioperative factors for post-LTx AKI include cardiopulmonary failure, vasopressor requirement,
hemodynamic effects of prolonged surgery, and blood loss/RBC transfusion [18,24,25,39,48,54,65].
Moreover, it has been hypothesized that HIRI is an important cause of post-LTx AKI [37,38]. Aspartate
aminotransferase (AST), as a surrogate marker for HIRI, has been shown to be correlated with post-LTx
AKI. [38,78] HIRI has a close relationship with the systemic inflammatory response, which in turn
is related to AKI and multiorgan dysfunction in similar settings such as sepsis [37]. Early hepatic
graft dysfunction has also been shown to be associated to post-LTx AKI [98]. In addition, recipients
of donation after circulatory death (DCD) grafts are reported to have a higher incidence of post-LTx
AKI compared to donation after brain death (DBD grafts). After DCD LTx, peak AST levels were
an independent predictor of post-LTx AKI [99]. Other known factors that influence HIRI such as
donor age, cold and warm ischemia times and graft steatosis have also been associated with post-LTx
AKI [37].
As demonstrated in our study, post-LTx AKI is associated with an increased risk of death
and liver graft failure. Several pharmacological and non-pharmacological interventions have been
studied, but so far these have failed to demonstrate any significant benefit in the prevention
of post-LTx AKI [37,100,101]. To continue efforts to mitigate post-LTx AKI, it is important to
identify those who are at high-risk for post-LTx AKI in order to develop earlier protective
strategies [37]. There have been many attempts to develop predictive models for post-LTx AKI [37].
Seven published predictive models addressing a diverse range of AKI definitions for post-LT AKI
have been developed [19,23,24,33,47,54,55]. However, the numbers of patients in these studies were
limited [19,23,24,33,47,54,55], and future prospective external validation, ideally with multi-center
studies with large number of patients, is required.
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Several limitations in our meta-analysis are worth mentioning. First, there were statistical
heterogeneities present in our study. Possible sources for heterogeneities were the differences in
the patient characteristics in the individual studies. However, we performed a meta-regression
analysis which demonstrated that the type of donor (deceased vs. living donors); the year of study did
not significantly affect the incidence of post-LTx AKI. Second, there is a lack of data from included
studies on novel AKI biomarkers. Novel biomarkers for AKI are emerging and could be useful for the
early identification and characterization of AKI. Thus, future studies evaluating predictive models
with novel biomarkers are needed. Lastly, this is a systematic review and meta-analysis of cohort
studies. Thus, it can demonstrate associations of post-LTx AKI with increased risk of mortality and
liver graft failure, but not a causal relationship.
5. Conclusions
In conclusion, there are overall high incidence rates of post-LTx AKI and severe AKI requiring
RRT of 40.8% and 7.0%. Post-LTx AKI is significantly associated with increased mortality and liver
graft failure. In addition, the incidence of post-LTx AKI has remained stable over time. This study
provides an epidemiological perspective to support the need for future large-scale multi-center studies
to identify preventive strategies for post-LTx AKI.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/3/372/s1,
Figure S1: Funnel plot evaluating for publication bias evaluating incidence of post-LTx AKI.
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